Enviar búsqueda
Cargar
doing business in the us (pharma-medical device)
•
3 recomendaciones
•
619 vistas
Jean-Xtophe Ordonneau
Seguir
20 year of experience shorted in a slideshow by french lawyer based in NYC
Leer menos
Leer más
Empresariales
Denunciar
Compartir
Denunciar
Compartir
1 de 30
Descargar ahora
Descargar para leer sin conexión
Recomendados
GMP Review -- Legal Letter from America Column -- How Data Integrity Issues S...
GMP Review -- Legal Letter from America Column -- How Data Integrity Issues S...
Michael Swit
Generic Drug Labeling Proposed Rule: The Generic Drug Industry Perspective
Generic Drug Labeling Proposed Rule: The Generic Drug Industry Perspective
Michael Swit
Self identification
Self identification
Gautam Halder
FDA Regulation of Drug and Device Advertising and Promotion -- The Basics
FDA Regulation of Drug and Device Advertising and Promotion -- The Basics
Michael Swit
FDA Regulation of Promotion & Advertising -- Part 1: The Basics
FDA Regulation of Promotion & Advertising -- Part 1: The Basics
Michael Swit
Labeling/Advertising and Promotion, Import/Export, and Enforcement Actions
Labeling/Advertising and Promotion, Import/Export, and Enforcement Actions
Michael Swit
Medical Device Advertising Law & Regulation
Medical Device Advertising Law & Regulation
Michael Swit
Para i iv orange book
Para i iv orange book
Altacit Global
Recomendados
GMP Review -- Legal Letter from America Column -- How Data Integrity Issues S...
GMP Review -- Legal Letter from America Column -- How Data Integrity Issues S...
Michael Swit
Generic Drug Labeling Proposed Rule: The Generic Drug Industry Perspective
Generic Drug Labeling Proposed Rule: The Generic Drug Industry Perspective
Michael Swit
Self identification
Self identification
Gautam Halder
FDA Regulation of Drug and Device Advertising and Promotion -- The Basics
FDA Regulation of Drug and Device Advertising and Promotion -- The Basics
Michael Swit
FDA Regulation of Promotion & Advertising -- Part 1: The Basics
FDA Regulation of Promotion & Advertising -- Part 1: The Basics
Michael Swit
Labeling/Advertising and Promotion, Import/Export, and Enforcement Actions
Labeling/Advertising and Promotion, Import/Export, and Enforcement Actions
Michael Swit
Medical Device Advertising Law & Regulation
Medical Device Advertising Law & Regulation
Michael Swit
Para i iv orange book
Para i iv orange book
Altacit Global
What’s In a Name? FDA and Non-Proprietary Names for Biologics/Biosimilars
What’s In a Name? FDA and Non-Proprietary Names for Biologics/Biosimilars
Michael Swit
FDA Regulation of Promotion & Advertising --Part 2: Direct-to-Consumer Ads
FDA Regulation of Promotion & Advertising --Part 2: Direct-to-Consumer Ads
Michael Swit
FDA Regulation of Promotion & Advertising -- Part 6: First Amendment, Off-La...
FDA Regulation of Promotion & Advertising -- Part 6: First Amendment, Off-La...
Michael Swit
The Basics of the Waxman-Hatch Act
The Basics of the Waxman-Hatch Act
Michael Swit
Regulatory opportunities for IP attorneys 2010
Regulatory opportunities for IP attorneys 2010
Kulkarni Law Firm
Yuvraj Regmi on Hatch-Waxman Act and Amendments and CFR
Yuvraj Regmi on Hatch-Waxman Act and Amendments and CFR
YUVRAJ REGMI
Study of Marketing Conditions for Marketing Authorization of Over The Counter...
Study of Marketing Conditions for Marketing Authorization of Over The Counter...
Aakashdeep Raval
New Drug Application In India and US.
New Drug Application In India and US.
sopansanap1
Hatch waxman act
Hatch waxman act
deepika velu
Hatch Waxman Act
Hatch Waxman Act
Naveen Kumar
Hatch- waxman act (The drug price competition and patent term restoration act...
Hatch- waxman act (The drug price competition and patent term restoration act...
Mohit Kumar
FDA Regulation of Combination Products
FDA Regulation of Combination Products
Michael Swit
hatch-waxman act@amendments
hatch-waxman act@amendments
Bharati vidyapeeth college of pharmacy, kolhapur
A) Study in detail about Para - IV filing. B) Case studies for Para - IV Filing.
A) Study in detail about Para - IV filing. B) Case studies for Para - IV Filing.
Aakashdeep Raval
Federal Regulatory Issues Us Food And Drug Administration Medical Device Amen...
Federal Regulatory Issues Us Food And Drug Administration Medical Device Amen...
Jacobe2008
The hatch waxman act
The hatch waxman act
Pranav Agrawal
Generic Damages in Life Sciences Patent Litigation: Strategic Considerations
Generic Damages in Life Sciences Patent Litigation: Strategic Considerations
This account is closed
Ethics and the Law: The Case of Myriad Genetics, Ethics in Patenting and Eth...
Ethics and the Law: The Case of Myriad Genetics, Ethics in Patenting and Eth...
Kirby Drake
Regulation of labeling and promotion
Regulation of labeling and promotion
Alaa 3esmat.Cairo Sy essmat
Medical device reporting 27 sep2016
Medical device reporting 27 sep2016
Ann-Marie Roche
Left Productions, la vidéo en ligne pour générer des revenus
Left Productions, la vidéo en ligne pour générer des revenus
Jean-Xtophe Ordonneau
doing business in the us
doing business in the us
Jean-Xtophe Ordonneau
Más contenido relacionado
La actualidad más candente
What’s In a Name? FDA and Non-Proprietary Names for Biologics/Biosimilars
What’s In a Name? FDA and Non-Proprietary Names for Biologics/Biosimilars
Michael Swit
FDA Regulation of Promotion & Advertising --Part 2: Direct-to-Consumer Ads
FDA Regulation of Promotion & Advertising --Part 2: Direct-to-Consumer Ads
Michael Swit
FDA Regulation of Promotion & Advertising -- Part 6: First Amendment, Off-La...
FDA Regulation of Promotion & Advertising -- Part 6: First Amendment, Off-La...
Michael Swit
The Basics of the Waxman-Hatch Act
The Basics of the Waxman-Hatch Act
Michael Swit
Regulatory opportunities for IP attorneys 2010
Regulatory opportunities for IP attorneys 2010
Kulkarni Law Firm
Yuvraj Regmi on Hatch-Waxman Act and Amendments and CFR
Yuvraj Regmi on Hatch-Waxman Act and Amendments and CFR
YUVRAJ REGMI
Study of Marketing Conditions for Marketing Authorization of Over The Counter...
Study of Marketing Conditions for Marketing Authorization of Over The Counter...
Aakashdeep Raval
New Drug Application In India and US.
New Drug Application In India and US.
sopansanap1
Hatch waxman act
Hatch waxman act
deepika velu
Hatch Waxman Act
Hatch Waxman Act
Naveen Kumar
Hatch- waxman act (The drug price competition and patent term restoration act...
Hatch- waxman act (The drug price competition and patent term restoration act...
Mohit Kumar
FDA Regulation of Combination Products
FDA Regulation of Combination Products
Michael Swit
hatch-waxman act@amendments
hatch-waxman act@amendments
Bharati vidyapeeth college of pharmacy, kolhapur
A) Study in detail about Para - IV filing. B) Case studies for Para - IV Filing.
A) Study in detail about Para - IV filing. B) Case studies for Para - IV Filing.
Aakashdeep Raval
Federal Regulatory Issues Us Food And Drug Administration Medical Device Amen...
Federal Regulatory Issues Us Food And Drug Administration Medical Device Amen...
Jacobe2008
The hatch waxman act
The hatch waxman act
Pranav Agrawal
Generic Damages in Life Sciences Patent Litigation: Strategic Considerations
Generic Damages in Life Sciences Patent Litigation: Strategic Considerations
This account is closed
Ethics and the Law: The Case of Myriad Genetics, Ethics in Patenting and Eth...
Ethics and the Law: The Case of Myriad Genetics, Ethics in Patenting and Eth...
Kirby Drake
Regulation of labeling and promotion
Regulation of labeling and promotion
Alaa 3esmat.Cairo Sy essmat
Medical device reporting 27 sep2016
Medical device reporting 27 sep2016
Ann-Marie Roche
La actualidad más candente
(20)
What’s In a Name? FDA and Non-Proprietary Names for Biologics/Biosimilars
What’s In a Name? FDA and Non-Proprietary Names for Biologics/Biosimilars
FDA Regulation of Promotion & Advertising --Part 2: Direct-to-Consumer Ads
FDA Regulation of Promotion & Advertising --Part 2: Direct-to-Consumer Ads
FDA Regulation of Promotion & Advertising -- Part 6: First Amendment, Off-La...
FDA Regulation of Promotion & Advertising -- Part 6: First Amendment, Off-La...
The Basics of the Waxman-Hatch Act
The Basics of the Waxman-Hatch Act
Regulatory opportunities for IP attorneys 2010
Regulatory opportunities for IP attorneys 2010
Yuvraj Regmi on Hatch-Waxman Act and Amendments and CFR
Yuvraj Regmi on Hatch-Waxman Act and Amendments and CFR
Study of Marketing Conditions for Marketing Authorization of Over The Counter...
Study of Marketing Conditions for Marketing Authorization of Over The Counter...
New Drug Application In India and US.
New Drug Application In India and US.
Hatch waxman act
Hatch waxman act
Hatch Waxman Act
Hatch Waxman Act
Hatch- waxman act (The drug price competition and patent term restoration act...
Hatch- waxman act (The drug price competition and patent term restoration act...
FDA Regulation of Combination Products
FDA Regulation of Combination Products
hatch-waxman act@amendments
hatch-waxman act@amendments
A) Study in detail about Para - IV filing. B) Case studies for Para - IV Filing.
A) Study in detail about Para - IV filing. B) Case studies for Para - IV Filing.
Federal Regulatory Issues Us Food And Drug Administration Medical Device Amen...
Federal Regulatory Issues Us Food And Drug Administration Medical Device Amen...
The hatch waxman act
The hatch waxman act
Generic Damages in Life Sciences Patent Litigation: Strategic Considerations
Generic Damages in Life Sciences Patent Litigation: Strategic Considerations
Ethics and the Law: The Case of Myriad Genetics, Ethics in Patenting and Eth...
Ethics and the Law: The Case of Myriad Genetics, Ethics in Patenting and Eth...
Regulation of labeling and promotion
Regulation of labeling and promotion
Medical device reporting 27 sep2016
Medical device reporting 27 sep2016
Destacado
Left Productions, la vidéo en ligne pour générer des revenus
Left Productions, la vidéo en ligne pour générer des revenus
Jean-Xtophe Ordonneau
doing business in the us
doing business in the us
Jean-Xtophe Ordonneau
Manipulation positive et ses applications pratiques (Par Philippe Massol)
Manipulation positive et ses applications pratiques (Par Philippe Massol)
Jean-Xtophe Ordonneau
Les retours accélérés : ce que l’Intelligence Artificielle va changer pour vo...
Les retours accélérés : ce que l’Intelligence Artificielle va changer pour vo...
Jean-Xtophe Ordonneau
TubeReach, l'agence Pure Player YouTube
TubeReach, l'agence Pure Player YouTube
Jean-Xtophe Ordonneau
Effectuation : Comment les entrepreneurs fonctionnent (Par Philippe Silberzahn)
Effectuation : Comment les entrepreneurs fonctionnent (Par Philippe Silberzahn)
Jean-Xtophe Ordonneau
Destacado
(6)
Left Productions, la vidéo en ligne pour générer des revenus
Left Productions, la vidéo en ligne pour générer des revenus
doing business in the us
doing business in the us
Manipulation positive et ses applications pratiques (Par Philippe Massol)
Manipulation positive et ses applications pratiques (Par Philippe Massol)
Les retours accélérés : ce que l’Intelligence Artificielle va changer pour vo...
Les retours accélérés : ce que l’Intelligence Artificielle va changer pour vo...
TubeReach, l'agence Pure Player YouTube
TubeReach, l'agence Pure Player YouTube
Effectuation : Comment les entrepreneurs fonctionnent (Par Philippe Silberzahn)
Effectuation : Comment les entrepreneurs fonctionnent (Par Philippe Silberzahn)
Similar a doing business in the us (pharma-medical device)
FDA Approved vs FDA Cleared
FDA Approved vs FDA Cleared
EMMAIntl
Why Compliance is a Tough Pill to Swallow – Nutraceuticals
Why Compliance is a Tough Pill to Swallow – Nutraceuticals
Affiliate Summit
Regulatory Affairs Interview Questions .pdf
Regulatory Affairs Interview Questions .pdf
Priyansha Singh
New drug application (NDA).pptx
New drug application (NDA).pptx
Shiva Kant Thakur
FDA Enforcement – Trends, Powers and Penalties Or “Why Crime Does Not Pay”
FDA Enforcement – Trends, Powers and Penalties Or “Why Crime Does Not Pay”
Michael Swit
FDA Enforcement: The Cop is Back – How Enhanced Enforcement Can Impact You a...
FDA Enforcement: The Cop is Back – How Enhanced Enforcement Can Impact You a...
Michael Swit
FDA Regulation of Promotion & Advertising Part 7: FTC Regulation
FDA Regulation of Promotion & Advertising Part 7: FTC Regulation
Michael Swit
Pharma Uptoday Monthly Magazine Volume 21; Issue Dec 2015
Pharma Uptoday Monthly Magazine Volume 21; Issue Dec 2015
Sathish Vemula
Orphan Drugs – the Challenges and Benefits of Navigating FDA’s Regime Governi...
Orphan Drugs – the Challenges and Benefits of Navigating FDA’s Regime Governi...
Michael Swit
FDA Regulation of Promotion & Advertising -- Part 7: FTC Regulation
FDA Regulation of Promotion & Advertising -- Part 7: FTC Regulation
Michael Swit
A Regulatory Strategy for your Medical Device
A Regulatory Strategy for your Medical Device
EMMAIntl
Indusrty and Fda liasions
Indusrty and Fda liasions
ROHIT
FDA Regulation of Promotion & Advertising -- Part 7: FTC Regulation
FDA Regulation of Promotion & Advertising -- Part 7: FTC Regulation
Michael Swit
COVID-19 and the FDA: What Every Manufacturing Company Needs to Know
COVID-19 and the FDA: What Every Manufacturing Company Needs to Know
EMMAIntl
industry and FDA liaisons
industry and FDA liaisons
fouza ameer
Regulatory 101
Regulatory 101
The Capital Network
Drug Delivery -- Perspectives on the FDA Regulatory Environment
Drug Delivery -- Perspectives on the FDA Regulatory Environment
Michael Swit
HEDGING PIPELINE RISK IN PHARMA FDA Swaps and Annuities 3.2015
HEDGING PIPELINE RISK IN PHARMA FDA Swaps and Annuities 3.2015
Tomas J. Philipson
Credit Suisse Healthcare Conference
Credit Suisse Healthcare Conference
ImpaxLaboratories
Regulatory affair - Introduction
Regulatory affair - Introduction
Dr. Jigar Vyas
Similar a doing business in the us (pharma-medical device)
(20)
FDA Approved vs FDA Cleared
FDA Approved vs FDA Cleared
Why Compliance is a Tough Pill to Swallow – Nutraceuticals
Why Compliance is a Tough Pill to Swallow – Nutraceuticals
Regulatory Affairs Interview Questions .pdf
Regulatory Affairs Interview Questions .pdf
New drug application (NDA).pptx
New drug application (NDA).pptx
FDA Enforcement – Trends, Powers and Penalties Or “Why Crime Does Not Pay”
FDA Enforcement – Trends, Powers and Penalties Or “Why Crime Does Not Pay”
FDA Enforcement: The Cop is Back – How Enhanced Enforcement Can Impact You a...
FDA Enforcement: The Cop is Back – How Enhanced Enforcement Can Impact You a...
FDA Regulation of Promotion & Advertising Part 7: FTC Regulation
FDA Regulation of Promotion & Advertising Part 7: FTC Regulation
Pharma Uptoday Monthly Magazine Volume 21; Issue Dec 2015
Pharma Uptoday Monthly Magazine Volume 21; Issue Dec 2015
Orphan Drugs – the Challenges and Benefits of Navigating FDA’s Regime Governi...
Orphan Drugs – the Challenges and Benefits of Navigating FDA’s Regime Governi...
FDA Regulation of Promotion & Advertising -- Part 7: FTC Regulation
FDA Regulation of Promotion & Advertising -- Part 7: FTC Regulation
A Regulatory Strategy for your Medical Device
A Regulatory Strategy for your Medical Device
Indusrty and Fda liasions
Indusrty and Fda liasions
FDA Regulation of Promotion & Advertising -- Part 7: FTC Regulation
FDA Regulation of Promotion & Advertising -- Part 7: FTC Regulation
COVID-19 and the FDA: What Every Manufacturing Company Needs to Know
COVID-19 and the FDA: What Every Manufacturing Company Needs to Know
industry and FDA liaisons
industry and FDA liaisons
Regulatory 101
Regulatory 101
Drug Delivery -- Perspectives on the FDA Regulatory Environment
Drug Delivery -- Perspectives on the FDA Regulatory Environment
HEDGING PIPELINE RISK IN PHARMA FDA Swaps and Annuities 3.2015
HEDGING PIPELINE RISK IN PHARMA FDA Swaps and Annuities 3.2015
Credit Suisse Healthcare Conference
Credit Suisse Healthcare Conference
Regulatory affair - Introduction
Regulatory affair - Introduction
Más de Jean-Xtophe Ordonneau
Bo Burlingham : Finish Big
Bo Burlingham : Finish Big
Jean-Xtophe Ordonneau
Altman Partners : l'Entreprise libérée
Altman Partners : l'Entreprise libérée
Jean-Xtophe Ordonneau
Christine Blondel : la transmission des entreprises familiales
Christine Blondel : la transmission des entreprises familiales
Jean-Xtophe Ordonneau
Des projets de transport en France avec une forte rentabilité
Des projets de transport en France avec une forte rentabilité
Jean-Xtophe Ordonneau
Les effets économiques des infrastructures de transport
Les effets économiques des infrastructures de transport
Jean-Xtophe Ordonneau
Présentation de Bankapart (Par Frédéric Honnorat)
Présentation de Bankapart (Par Frédéric Honnorat)
Jean-Xtophe Ordonneau
Investbook : le crowdfunding par souscription d'obligations (Par Patrick Hann...
Investbook : le crowdfunding par souscription d'obligations (Par Patrick Hann...
Jean-Xtophe Ordonneau
Les rapports entre investisseurs et entrepreneurs : une question d'ADN (Par J...
Les rapports entre investisseurs et entrepreneurs : une question d'ADN (Par J...
Jean-Xtophe Ordonneau
Et si votre entreprise émettait des obligations ? (Par David Aubin)
Et si votre entreprise émettait des obligations ? (Par David Aubin)
Jean-Xtophe Ordonneau
Présentation Marc Thouvenin_Marketing Online Melcion 23062015
Présentation Marc Thouvenin_Marketing Online Melcion 23062015
Jean-Xtophe Ordonneau
Conference ESLSCA de Thierry Willieme
Conference ESLSCA de Thierry Willieme
Jean-Xtophe Ordonneau
Présentation de la tri-fonctionnalité
Présentation de la tri-fonctionnalité
Jean-Xtophe Ordonneau
La trifonctionnalité
La trifonctionnalité
Jean-Xtophe Ordonneau
Présentation Spöka_Séminaire Marketing Online Melcion_23062015
Présentation Spöka_Séminaire Marketing Online Melcion_23062015
Jean-Xtophe Ordonneau
Les actions de préférence, un instrument juridique adapté aux besoins des ent...
Les actions de préférence, un instrument juridique adapté aux besoins des ent...
Jean-Xtophe Ordonneau
Les nouveaux entrepreneurs et les nouveaux business modèles : retour du TechC...
Les nouveaux entrepreneurs et les nouveaux business modèles : retour du TechC...
Jean-Xtophe Ordonneau
Leadership authentique, épanouissement et performance (Par Vincent Giolito)
Leadership authentique, épanouissement et performance (Par Vincent Giolito)
Jean-Xtophe Ordonneau
Convaincre à coup sûr ? Présentations PowerPoint (Par Sophie Gerlin)
Convaincre à coup sûr ? Présentations PowerPoint (Par Sophie Gerlin)
Jean-Xtophe Ordonneau
Ce que le cheval nous apprend en matière de leadership (Par Franck Petetin)
Ce que le cheval nous apprend en matière de leadership (Par Franck Petetin)
Jean-Xtophe Ordonneau
OPTR : On Peut Tout Réinventer (Par Bertrand Petit)
OPTR : On Peut Tout Réinventer (Par Bertrand Petit)
Jean-Xtophe Ordonneau
Más de Jean-Xtophe Ordonneau
(20)
Bo Burlingham : Finish Big
Bo Burlingham : Finish Big
Altman Partners : l'Entreprise libérée
Altman Partners : l'Entreprise libérée
Christine Blondel : la transmission des entreprises familiales
Christine Blondel : la transmission des entreprises familiales
Des projets de transport en France avec une forte rentabilité
Des projets de transport en France avec une forte rentabilité
Les effets économiques des infrastructures de transport
Les effets économiques des infrastructures de transport
Présentation de Bankapart (Par Frédéric Honnorat)
Présentation de Bankapart (Par Frédéric Honnorat)
Investbook : le crowdfunding par souscription d'obligations (Par Patrick Hann...
Investbook : le crowdfunding par souscription d'obligations (Par Patrick Hann...
Les rapports entre investisseurs et entrepreneurs : une question d'ADN (Par J...
Les rapports entre investisseurs et entrepreneurs : une question d'ADN (Par J...
Et si votre entreprise émettait des obligations ? (Par David Aubin)
Et si votre entreprise émettait des obligations ? (Par David Aubin)
Présentation Marc Thouvenin_Marketing Online Melcion 23062015
Présentation Marc Thouvenin_Marketing Online Melcion 23062015
Conference ESLSCA de Thierry Willieme
Conference ESLSCA de Thierry Willieme
Présentation de la tri-fonctionnalité
Présentation de la tri-fonctionnalité
La trifonctionnalité
La trifonctionnalité
Présentation Spöka_Séminaire Marketing Online Melcion_23062015
Présentation Spöka_Séminaire Marketing Online Melcion_23062015
Les actions de préférence, un instrument juridique adapté aux besoins des ent...
Les actions de préférence, un instrument juridique adapté aux besoins des ent...
Les nouveaux entrepreneurs et les nouveaux business modèles : retour du TechC...
Les nouveaux entrepreneurs et les nouveaux business modèles : retour du TechC...
Leadership authentique, épanouissement et performance (Par Vincent Giolito)
Leadership authentique, épanouissement et performance (Par Vincent Giolito)
Convaincre à coup sûr ? Présentations PowerPoint (Par Sophie Gerlin)
Convaincre à coup sûr ? Présentations PowerPoint (Par Sophie Gerlin)
Ce que le cheval nous apprend en matière de leadership (Par Franck Petetin)
Ce que le cheval nous apprend en matière de leadership (Par Franck Petetin)
OPTR : On Peut Tout Réinventer (Par Bertrand Petit)
OPTR : On Peut Tout Réinventer (Par Bertrand Petit)
Último
Darshan Hiranandani [News About Next CEO].pdf
Darshan Hiranandani [News About Next CEO].pdf
Shashank Mehta
TriStar Gold Corporate Presentation - April 2024
TriStar Gold Corporate Presentation - April 2024
Adnet Communications
International Business Environments and Operations 16th Global Edition test b...
International Business Environments and Operations 16th Global Edition test b...
ssuserf63bd7
Digital Transformation in the PLM domain - distrib.pdf
Digital Transformation in the PLM domain - distrib.pdf
Jos Voskuil
Marketplace and Quality Assurance Presentation - Vincent Chirchir
Marketplace and Quality Assurance Presentation - Vincent Chirchir
ictsugar
Independent Call Girls Andheri Nightlaila 9967584737
Independent Call Girls Andheri Nightlaila 9967584737
Riya Pathan
MAHA Global and IPR: Do Actions Speak Louder Than Words?
MAHA Global and IPR: Do Actions Speak Louder Than Words?
Olivia Kresic
8447779800, Low rate Call girls in Kotla Mubarakpur Delhi NCR
8447779800, Low rate Call girls in Kotla Mubarakpur Delhi NCR
ashishs7044
Call Us ➥9319373153▻Call Girls In North Goa
Call Us ➥9319373153▻Call Girls In North Goa
Call girls in Goa, +91 9319373153 Escort Service in North Goa
Church Building Grants To Assist With New Construction, Additions, And Restor...
Church Building Grants To Assist With New Construction, Additions, And Restor...
Americas Got Grants
Kenya Coconut Production Presentation by Dr. Lalith Perera
Kenya Coconut Production Presentation by Dr. Lalith Perera
ictsugar
8447779800, Low rate Call girls in Shivaji Enclave Delhi NCR
8447779800, Low rate Call girls in Shivaji Enclave Delhi NCR
ashishs7044
Global Scenario On Sustainable and Resilient Coconut Industry by Dr. Jelfina...
Global Scenario On Sustainable and Resilient Coconut Industry by Dr. Jelfina...
ictsugar
(Best) ENJOY Call Girls in Faridabad Ex | 8377087607
(Best) ENJOY Call Girls in Faridabad Ex | 8377087607
dollysharma2066
Youth Involvement in an Innovative Coconut Value Chain by Mwalimu Menza
Youth Involvement in an Innovative Coconut Value Chain by Mwalimu Menza
ictsugar
PSCC - Capability Statement Presentation
PSCC - Capability Statement Presentation
Anamaria Contreras
Guide Complete Set of Residential Architectural Drawings PDF
Guide Complete Set of Residential Architectural Drawings PDF
Chandresh Chudasama
The-Ethical-issues-ghhhhhhhhjof-Byjus.pptx
The-Ethical-issues-ghhhhhhhhjof-Byjus.pptx
mbikashkanyari
Annual General Meeting Presentation Slides
Annual General Meeting Presentation Slides
KeppelCorporation
Corporate Profile 47Billion Information Technology
Corporate Profile 47Billion Information Technology
Data Analytics Company - 47Billion Inc.
Último
(20)
Darshan Hiranandani [News About Next CEO].pdf
Darshan Hiranandani [News About Next CEO].pdf
TriStar Gold Corporate Presentation - April 2024
TriStar Gold Corporate Presentation - April 2024
International Business Environments and Operations 16th Global Edition test b...
International Business Environments and Operations 16th Global Edition test b...
Digital Transformation in the PLM domain - distrib.pdf
Digital Transformation in the PLM domain - distrib.pdf
Marketplace and Quality Assurance Presentation - Vincent Chirchir
Marketplace and Quality Assurance Presentation - Vincent Chirchir
Independent Call Girls Andheri Nightlaila 9967584737
Independent Call Girls Andheri Nightlaila 9967584737
MAHA Global and IPR: Do Actions Speak Louder Than Words?
MAHA Global and IPR: Do Actions Speak Louder Than Words?
8447779800, Low rate Call girls in Kotla Mubarakpur Delhi NCR
8447779800, Low rate Call girls in Kotla Mubarakpur Delhi NCR
Call Us ➥9319373153▻Call Girls In North Goa
Call Us ➥9319373153▻Call Girls In North Goa
Church Building Grants To Assist With New Construction, Additions, And Restor...
Church Building Grants To Assist With New Construction, Additions, And Restor...
Kenya Coconut Production Presentation by Dr. Lalith Perera
Kenya Coconut Production Presentation by Dr. Lalith Perera
8447779800, Low rate Call girls in Shivaji Enclave Delhi NCR
8447779800, Low rate Call girls in Shivaji Enclave Delhi NCR
Global Scenario On Sustainable and Resilient Coconut Industry by Dr. Jelfina...
Global Scenario On Sustainable and Resilient Coconut Industry by Dr. Jelfina...
(Best) ENJOY Call Girls in Faridabad Ex | 8377087607
(Best) ENJOY Call Girls in Faridabad Ex | 8377087607
Youth Involvement in an Innovative Coconut Value Chain by Mwalimu Menza
Youth Involvement in an Innovative Coconut Value Chain by Mwalimu Menza
PSCC - Capability Statement Presentation
PSCC - Capability Statement Presentation
Guide Complete Set of Residential Architectural Drawings PDF
Guide Complete Set of Residential Architectural Drawings PDF
The-Ethical-issues-ghhhhhhhhjof-Byjus.pptx
The-Ethical-issues-ghhhhhhhhjof-Byjus.pptx
Annual General Meeting Presentation Slides
Annual General Meeting Presentation Slides
Corporate Profile 47Billion Information Technology
Corporate Profile 47Billion Information Technology
doing business in the us (pharma-medical device)
1.
The Essentials for
Pharmaceutical and Medical Device Companies Desiring to Enter the U.S. Market The Structural and Legal ‘Need-to-Knows’ for French and European Pharmaceutical and Medical Device Companies Philippe C.M. Manteau © 2012 Schiff Hardin LLP. All rights reserved.
2.
The Background • A
businessperson in the pharmaceutical/medical device industry wants to enter the U.S. market • Overall concern: ensure that activities are appropriately structured in a manner most beneficial for his or her company and shareholders • Specific concerns: – FDA – LLC Structure – Products Liability – Corporate Structure – Distributor vs. Agent – Employment Issues – Intellectual Property – U.S. Equity Incentives – Key Provisions in the Contract – Immigration – A Representative U.S. Office – M&A Considerations 2 © 2012 Schiff Hardin LLP. All rights reserved.
3.
Consideration #1: Working
with the FDA The Food and Drug Administration (FDA) is the U.S. agency responsible for protecting and promoting public health through the regulation and supervision of, among other things, pharmaceuticals, medical devices, dietary supplements and cosmetics FDA Regulation of Medical Devices ● “Medical devices” is defined broadly and includes such things as hospital and laboratory equipment, cosmetic devices and surgical devices ● Approval Process - The FDA classifies medical devices into three categories – Class I, II and III (III being the riskiest). The class determines which approval process a marketer must undergo. – 510(k) Pre-market Notification – 99% of medical devices enter the U.S. market through this process (e.g., Class I and Class II) – Premarket Approval Application (PMA) – approval process for Class III devices FDA Regulation of Pharmaceuticals ● New Drug Application (NDA) ● Abbreviated New Drug Application (ANDA) ● Companies need to adhere to drug labeling and manufacturing standards 3 © 2012 Schiff Hardin LLP. All rights reserved.
4.
Consideration #1: FDA
and Medical Devices: the 510(k) Process 510(k): An entity that wants to market a device for human use in the United States must submit a 510(k) notification to the FDA at least 90 days before marketing, unless such entity is exempt or goes through the more onerous PMA process (described on the next page). The notification must demonstrate that the proposed device is safe and effective, by showing that the device is “substantially equivalent” to a “legally marketed device” (the “SE test”). ● A “legally marketed device” includes a device that was legally marketed before May 28, 1976 (hence, grandfathered into the current regulations), a device for which a more onerous PMA is not required, as well as devices that were previously classified as Class III, but have been reclassified to a less risky class (i.e., Class I or II). ● Once submitted, the marketer must wait for an order from the FDA declaring that the device has met the SE test. Once received, marketing may begin. ● Note that, although the 510(k) process is a notification, the marketer must still wait for a communication from the FDA before marketing can begin. Recently, the 510(k) process has been criticized for being too relaxed and many critics have pushed for stronger oversight. As such, it would not be surprising for the FDA to re- evaluate the 510(k) procedure in the near future. 4 © 2012 Schiff Hardin LLP. All rights reserved.
5.
Consideration #1: FDA
and Medical Devices: Premarket Approval PMA) • PMA: An application submitted to the FDA to request approval to market Class III devices. Class III devices include those that sustain human life or pose the greatest risk. As such, they face this most stringent type of device marketing application required by the FDA • Unlike a 510(k), PMA is based on a determination by the FDA that the PMA contains sufficient valid scientific evidence that provides reasonable assurance that the device is safe and effective for its intended use • Timeline – Within 45 days of receiving the PMA, the FDA notifies the applicant that the PMA has been received – The FDA then has 180 days to review the PMA (but generally, the review time is longer than this) 5 © 2012 Schiff Hardin LLP. All rights reserved.
6.
Consideration #1: FDA
and Pharmaceuticals New Drug Application (NDA): ● Process by which drug companies formally propose that the FDA approve a new pharmaceutical for sale and marketing in the United States ● The purpose of a NDA is to provide enough information to permit the FDA to determine: – Whether the drug is safe in its proposed use(s), and whether the benefits of the drug outweigh the risks – Whether the drug's proposed labeling (package insert) is appropriate and what it should contain – Whether the methods used in manufacturing the drug and the controls used to maintain the drug's quality are adequate to preserve the drug's identity, strength, quality, and purity Abbreviated New Drug Application (ANDA) - FDA review and ultimate approval of a generic drug product 6 © 2012 Schiff Hardin LLP. All rights reserved.
7.
Consideration #1: Health
Insurance Portability and Accountability Act of 1996 (“HIPAA”) All “Covered Entities” are subject to HIPAA ● A Covered Entity is a health care provider, a health plan, or a clearinghouse that submits bills electronically ● Business associates of the Covered Entity (i.e., those that use or access patient information on the Covered Entity’s behalf) are also subject to HIPAA ● A reseller to a Covered Entity may be considered a “business associate”: try to protect such reseller in the contract with such Covered Entity Pursuant to HIPAA’s Privacy Rule, a Covered Entity must protect the following health information about a patient: ● sent or stored in any form (written, verbal, electronic); ● that identifies the patient or can be used to identify the patient; and ● that generally is about a patient’s past, present and/or future treatment and payment of services. 7 © 2012 Schiff Hardin LLP. All rights reserved.
8.
Consideration #1: Corporate Officer
Liability for FDA Violations ● In 2011, the FDA issued prosecution guidelines that stated that corporate officers could be criminally liable for violations of the Food, Drug and Cosmetic Act (the act which gives the FDA its authority) based solely on their position with the company ● This means a corporate officer could be liable even if he or she had no knowledge of the illegal conduct ● This is known as the “Park Doctrine” ● Possible penalties – large fines, prohibition from providing any services to a regulated company, probation and/or jail time ● Minimize risk of possible violations by instituting a comprehensive compliance program 8 © 2012 Schiff Hardin LLP. All rights reserved.
9.
Consideration #2: Products
Liability ● If a person is injured by a defective product that is unreasonably dangerous or unsafe, the injured person may have a claim or cause of action against the company that designed, manufactured, sold, distributed, leased, or furnished the product ● The “product” includes medical devices and pharmaceuticals. The “defect” can be a design defect, a manufacturing defect or a warning defect (including a failure to warn) ● Product liability laws are determined at the state level and vary from state to state ● Parties cannot exclude liability for product defects altogether (i.e., in a contract) but there are ways to reduce the risk: – Insurance – one party asks another to list it as an additional insured – Shift or apportion the risk to another party through an indemnification provision in the contract - Note, however, this option does not provide protection against third parties (i.e., end-user customers) ● It is important to consult with your legal counsel so that you can effectively limit your products liability exposure 9 © 2012 Schiff Hardin LLP. All rights reserved.
10.
How do most
companies enter the United States? Entry into the United States—3 typical ways: – Direct sales into the United States – Establishing a subsidiary in the United States – Acquisitions in the United States 10 © 2012 Schiff Hardin LLP. All rights reserved.
11.
Direct sales into
the United States Many non-U.S. companies take this approach by licensing the product to a U.S. company. The benefit of this approach is that the non-U.S. company can take advantage of the U.S. company’s existing market knowledge. The downside is that returns will be limited as revenue will be shared. 11 © 2012 Schiff Hardin LLP. All rights reserved.
12.
Consideration #3: Distinguishing between
distributors and agents Distributor – think “buy-sell”: ● Distributor obtains title to products from principal ● Principal invoices distributor for products ● Distributor sets resale prices for products and is subject to risks and rewards associated with resale (e.g., loss/gain of profit, risks of delivery) Agent: ● Agent never obtains title to products ● Agent invoices principal for services rendered ● No “resale price maintenance” problem But in both cases – set up objectives (easier to terminate) 12 © 2012 Schiff Hardin LLP. All rights reserved.
13.
Consideration #4: Protecting intellectual
property (IP) ● Common law rights to trademarks exist ● Additional layer of protection by registering IP at the United States Patent and Trademark Office ● Many companies overlook the concept of patenting their software ● Check your IP before you expand into the United States 13 © 2012 Schiff Hardin LLP. All rights reserved.
14.
From the Oregonian,
July 9, 2009: “Chinese startup based in Eugene wants to sell inexpensive solar panels in U.S. A Chinese startup vying for a piece of the U.S. solar market has landed in Eugene, hoping to become a national player in the state’s growing photovoltaic industry. . . Centron Solar, whose Web site went live Thursday morning, is moving fast to sell and distribute bargain-priced solar panels made in China to the U.S. market, expected to be the world’s next big solar player. . .” 14 © 2012 Schiff Hardin LLP. All rights reserved.
15.
From the Portland
Business Journal, October 8, 2009: “Centron Solar changes name to Grape Solar Centron Solar once said it wants to be the Wal-Mart of solar energy. That may still be true. But now the company is trying to sound a little more like Apple Computers. . . Despite the fruit-themed logic, combined with the notion that grapes grow with the help of solar energy, the real cause of the name change is rooted in a lawsuit filed Sept. 28 in the U.S. District Court in Arizona. CentroSolar Group AG, a $440 million German solar products manufacturer, filed the trademark infringement lawsuit claiming Centron Solar was intentionally trying to confuse customers.” 15 © 2012 Schiff Hardin LLP. All rights reserved.
16.
Consideration #5: Key
provisions in commercial contracts ● Keep it U.S. law governed – EU protections not helpful if there is a litigation in the United States ● Think first of an “exit strategy” – one-year contracts automatically renewable unless terminated by either party, with or without reason, upon 60- or 90-days notice are common ● Craft IP sections carefully to ensure that IP is not “assigned”; draft know-how sections tightly to make sure know-how is only licensed in a limited manner, for a limited purpose, and is kept confidential (remember, only confidential know-how is protected IP) ● Watch out for warranty, liability and indemnification provisions: – Warranty: software, products or services should be sold “as is” but for the very limited warranty set forth in the contract (contracts should carve-out implied warranty of merchantability or warranty of fitness for a particular purpose) – Liability: contract should exclude consequential or incidental damages, and limit liability to only reimbursement of money received under the contract – Indemnification by product supplier, software publisher or service provider: contract should restrict indemnification to a limited IP infringement, while control over litigation should be retained 16 © 2012 Schiff Hardin LLP. All rights reserved.
17.
Consideration #6: Having
a “representative office” may be problematic ● Beware that an agent or branch in the United States, of a foreign principal, may subject such principal to U.S. tax on its revenues generated in the United States ● In reality, not frequently done but in some cases you can have a limited agency agreement to perform ministerial tasks for the parent ● When there is such a need, consider establishing a subsidiary 17 © 2012 Schiff Hardin LLP. All rights reserved.
18.
Establishing a subsidiary
in the United States After initiating direct sales into the United States… consider setting-up a foothold there. 18 © 2012 Schiff Hardin LLP. All rights reserved.
19.
Consideration #7: Do
you really need an LLC? ● What is an LLC? Google will tell you. ● What Google will not tell you: one generally should not form an LLC when the majority shareholder (a “member”) is a French corporation – French parent subject to U.S. income tax – Branch profit dividend tax: tax on “deemed distributed” dividends – Law not as developed - liability issues? ● LLCs are more commonly used “downstream” in order to bring in U.S. partners 19 © 2012 Schiff Hardin LLP. All rights reserved.
20.
Consideration #8: Try
a corporation first ● Easy to form ● Easy to maintain ● Capitalization easy to manage: – Remember to keep debt-to-equity ratio at a maximum of 1.5:1 – Augmentation of capital by way of “accrued paid in capital” – Disconnect between number of shares and amount of capital ● If a shareholder is not a 100% owner, consider the need for a shareholders agreement ● If a shareholder is a minority shareholder, remember to receive “tag-along” rights 20 © 2012 Schiff Hardin LLP. All rights reserved.
21.
Consideration #9: Labor
and employment law ● The concept of “at-will” employment ● The concept of discrimination ● If you have an executive, you will want an employment contract to avoid disputes over: – compensation issues – termination issues – non-competition issues ● Beware of 401(k) and other benefit issues upon any merger or acquisition in the United States 21 © 2012 Schiff Hardin LLP. All rights reserved.
22.
Consideration #10: U.S.
Stock as incentives? ● Usually part of an “equity incentive plan” to encourage employees to work to maximize a company’s profits and share in the future of a company ● Companies with U.S. stock option plans must comply with federal tax and securities rules ● Establishing a French stock option plan in the United States renders the incentive package more complicated to manage due to the requisite French vs. U.S. law analysis, but it avoids the inclusion of minority shareholders in a company’s subsidiary ● A U.S. stock option plan with a U.S. subsidiary is feasible and potential workarounds exist such as providing phantom rights (or profit-only interest in an LLC formed as an indirect subsidiary) ● Beware of valuation issues and consider shareholders agreements 22 © 2012 Schiff Hardin LLP. All rights reserved.
23.
Consideration #11: Immigration ●
“Do it yourself” is not usually sufficient ● Strongly advise hiring an immigration lawyer ● Understand the differences among visas: L1 (intracompany transferee), H1B (professional worker) and E2 (foreign investor) ● Discuss future plans with an attorney to avoid pitfalls (e.g., E2 is easy to obtain but conversion to a green card is difficult) 23 © 2012 Schiff Hardin LLP. All rights reserved.
24.
Consideration #12: Acquisitions
in the United States ● Managing your external growth in the United States… ● Or using acquisitions as a first step to penetrate the U.S. market (if you do so, think of creating a U.S. subsidiary as an SPV for the U.S. acquisition). ● One example – in 2008, Ipsen, a specialty pharmaceutical company based out of Paris, acquired three U.S. companies for $450 million – Vernalis Inc., Tercica, Inc. and Octagen Corp. in an effort to build what it called a “fully-fledged North American presence.” 24 © 2012 Schiff Hardin LLP. All rights reserved.
25.
Consideration #12: M&A
– asset vs. stock acquisitions ● Stock Acquisition (or joint venture) – will you acquire all or a control portion of the equity of target? – Watch for “change of control” issues – If buying at premium you do not get to reduce taxes ● Asset Acquisition: – Select the specific assets and liabilities to purchase or not purchase – “Cherry-pick” employees (no statutory obligation to transfer employees) ● Asset and Stock Acquisitions: – “Representations and Warranties” of seller are key – Escrow accounts are frequently used – Negotiate any earn-out payments – Do not forget non-compete/non-solicit provisions ● Tax Trick: The 338(h)(10) election under federal and many state laws to treat the stock deal as an asset deal – Step-up your tax basis and amortize your goodwill over 15 years 25 © 2012 Schiff Hardin LLP. All rights reserved.
26.
General Trends in
the Pharmaceutical Industry ● Researchers expect to see: – Significant growth in licensing – Increase in the number of mergers and consolidations ● Currently, the global pharmaceutical market is dominated by the United States – U.S. accounted for 29% of global pharmaceutical sales in 2009 – U.S. projected to remain the single largest pharmaceutical market, with sales of $320-330 billion in 2011 ● Growth in the generic drug industry as more patents begin to expire – In the U.S., generic drug sales are projected to reach $129.3 billion by 2014 26 © 2012 Schiff Hardin LLP. All rights reserved.
27.
About Schiff Hardin
LLP Schiff Hardin LLP was founded in 1864. Since then we have expanded with offices in Chicago and Lake Forest, Illinois; New York, New York; Washington, D.C.; Atlanta, Georgia; San Francisco, California; Boston, Massachusetts; Ann Arbor, Michigan; and Charlotte, North Carolina. As a general practice firm with local, regional, national, and international clients, Schiff Hardin has significant experience in most areas of the law. 27 © 2012 Schiff Hardin LLP. All rights reserved.
28.
About Our New
York Office In 1991, Schiff Hardin established an office in New York in response to a client's request and needs. Since that time, we have developed significant capabilities in complex general litigation, reinsurance, intellectual property, corporate and securities, real estate transactions and finance, estate planning and administration, labor and employment, international transactions, restructuring and bankruptcy, and an increasing array of other key legal services. Our New York office also serves as a focal point for our representation of overseas clients. 28 © 2012 Schiff Hardin LLP. All rights reserved.
29.
Philippe C.M. Manteau
Partner – Avocat aux Barreaux de New York et de Paris Philippe Manteau’s practice focuses on growth and mid-cap companies, governmental organizations, and individuals in the United States and abroad in the areas of corporate and business law, as well as technology transactions. The core of his practice consists of assisting French and other international private companies in their U.S. investments and pmanteau@schiffhardin.com cross-border transactions and litigation. U.S. Direct: (212) 745-0856 Mr. Manteau’s training and international experience allow him to identify, analyze, and resolve issues arising in cross-border U.S. Cell: (646) 251-9204 transactions for European and U.S. clients. PRACTICE AREAS Mr. Manteau is fluent in English, French and German. Corporate and Securities International ● Fordham University School of Law (LL.M., Corporate Intellectual Property Law and Finance, cum laude, 2006) Litigation ● Université Paris X - Nanterre (D.E.S.S., European Business Law, with honors, 1996) BAR ADMISSIONS ● Université Paris X - Nanterre (J.D., French, German New York and European Business Law, 1995) Paris, France ● Institut d'Études Politiques de Paris (M.B.A., Economics and Finance Section, 1993) 29 © 2012 Schiff Hardin LLP. All rights reserved.
30.
This publication has
been prepared for general information of clients and friends of the firm. It is not intended to provide legal advice with respect to any specific matter. Under rules applicable to the professional conduct of attorneys in various jurisdictions, it may be considered advertising material. Tax Matters: The advice contained in this memorandum is not intended or written to be used, and cannot be used by a taxpayer, for the purpose of avoiding penalties that may be imposed on the taxpayer under law. © 2012 Schiff Hardin LLP. All rights reserved.
Descargar ahora